Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF -5.33%95 EV-to-OCF is 32.26 as of Aug. 12, 2026, which is 2% above its 10-year median of 31.75. GuruFocus rates BGLAF with a GF Score™ of 95/100 and a GF Value™ of $13.21 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, BioGaia AB ranks worse than 81.31% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioGaia AB's Enterprise Value is $1,084.8 Mil.
BioGaia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $33.6 Mil. Therefore, BioGaia AB's EV-to-OCF for today is 32.26.
The historical rank and industry rank for BioGaia AB's EV-to-OCF or its related term are showing as below:
BGLAF'
s EV-to-OCF Range Over the Past 10 Years
Min: 20.73 Med: 31.75 Max: 59.69
Current: 32.26
During the past 13 years, the highest EV-to-OCF of BioGaia AB was 59.69. The lowest was 20.73. And the median was 31.75.
BGLAF's EV-to-OCF is ranked worse than 81.31% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs BGLAF: 32.26
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioGaia AB's share price for today is $11.55.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.365.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioGaia AB EV-to-OCF Related Terms
BioGaia AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioGaia AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioGaia AB's EV-to-OCF falls into.
BioGaia AB's current Enterprise Value is $1,084.8 Mil.
BioGaia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a EV-to-OCF of 32.26 as of Aug. 12, 2026. This is near median its historical median of 31.75. Over the past decade, BioGaia AB's EV-to-OCF has ranged from 20.73 to 59.69. According to the industry distribution chart, BioGaia AB ranks #818 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is BioGaia AB's EV-to-OCF too high?
BioGaia AB's current EV-to-OCF of 32.26 is near median its 10-year median of 31.75. Over the past 10 years, this metric has ranged from a low of 20.73 to a high of 59.69. The Drug Manufacturers industry median EV-to-OCF is 11.10. BioGaia AB's value of 32.26 is 190.6% above this industry median. Based on the distribution chart, BioGaia AB ranks #818 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #818 out of 1006 companies for EV-to-OCF. This places BioGaia AB in the lower half of its industry. The industry median EV-to-OCF is 11.10. BioGaia AB's value of 32.26 is 190.6% above this benchmark. Historically, BioGaia AB's own EV-to-OCF has ranged from 20.73 to 59.69 over the past decade. While the company's 10-year median is 31.75 vs. the industry median of 11.10, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current EV-to-OCF of 32.26 is 190.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current EV-to-OCF is 32.26, which is near median its own 10-year median of 31.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.21, compared to a current price of $11.55 — trading 12.6% below its estimated fair value. The current EV-to-OCF is 32.26, which is near median its 10-year median of 31.75 and 190.6% above the Drug Manufacturers industry median of 11.10. BioGaia AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current EV-to-OCF is 32.26 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $11.55 is trading 12.6% below its estimated GF Value™ of $13.21.
GuruFocus considers BioGaia AB to be Modestly Undervalued.
Key valuation signals for BGLAF:
EV-to-OCF: 32.26 (near median its 10-year median of 31.75)
GF Value™: $13.21 vs. price of $11.55 (12.6% below fair value)
Industry Position: 190.6% above the Drug Manufacturers median (#818 of 1006)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
95GF Score
Get the complete analysis for BGLAF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
